848324-33-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amide serves as a promising candidate for drug development due to its unique structure and functional groups. It can be utilized in the creation of novel therapeutic agents that target specific biological pathways or receptors, potentially leading to the discovery of new treatments for various diseases and conditions.
Further research and investigation into the properties and potential applications of 2-Amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amide are necessary to fully explore its capabilities and establish its role in the pharmaceutical and medical fields.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 107-91-5 cyanoacetic acid amide 
• 23462-75-1 5,6-dihydro-2H-pyran-3(4H)-one 

Relevant academic research and scientific papers

Structure–activity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity

During infection, the Gram-negative opportunistic pathogen Pseudomonas aeruginosa employs its type III secretion system to translocate the toxin exoenzyme S (ExoS) into the eukaryotic host cell cytoplasm. ExoS is an essential in vivo virulence factor that enables P. aeruginosa to avoid phagocytosis and eventually kill the host cell. ExoS elicits its pathogenicity mainly via ADP-ribosyltransferase (ADPRT) activity. We recently identified a new class of ExoS ADPRT inhibitors with in vitro IC50 of around 20 μM in an enzymatic assay using a recombinant ExoS ADPRT domain. Herein, we report structure–activity relationships of this compound class by comparing a total of 51 compounds based on a thieno [2,3-d]pyrimidin-4(3H)-one and 4-oxo-3,4-dihydroquinazoline scaffolds. Improved inhibitors with in vitro IC50 values of 6 μM were identified. Importantly, we demonstrated that the most potent inhibitors block ADPRT activity of native full-length ExoS secreted by viable P. aeruginosa with an IC50 value of 1.3 μM in an enzymatic assay. This compound class holds promise as starting point for development of novel antibacterial agents.

A novel series of positive modulators of the AMPA receptor: Discovery and structure based hit-to-lead studies

Starting from an HTS derived hit 1, application of biostructural data facilitated rapid optimization to lead 22, a novel AMPA receptor modulator. This is the first demonstration of how structure based drug design can be exploited in an optimization program for a glutamate receptor.

PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS

The present invention relates to a heterocyclic derivative according to Formula (I) wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceuti